Affronti, M. L., Woodring, S., Herndon, J. E., McSherry, F., Peters, K. B., Friedman, H. S., … Vredenburgh, J. J. (2012). A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. In NEURO-ONCOLOGY (Vol. 14, pp. 156–156). Washington, DC: OXFORD UNIV PRESS INC.

Affronti, Mary Lou, Sarah Woodring, James E. Herndon, Frances McSherry, Katherine B. Peters, Henry S. Friedman, Annick Desjardins, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In NEURO-ONCOLOGY, 14:156–156. OXFORD UNIV PRESS INC, 2012.

Affronti ML, Woodring S, Herndon JE, McSherry F, Peters KB, Friedman HS, et al. A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 156–156.

Affronti, Mary Lou, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” NEURO-ONCOLOGY, vol. 14, OXFORD UNIV PRESS INC, 2012, pp. 156–156.

Affronti ML, Woodring S, Herndon JE, McSherry F, Peters KB, Friedman HS, Desjardins A, Freeman W, Cheshire S, Cone C, Kalinowski KH, Kim J-Y, Lay HH, Poillucci V, Southerland C, Tetterton J, Vredenburgh JJ. A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 156–156.